Inhibition of T cell activation and autoimmune diabetes using a B cell surface–linked CTLA-4 agonist
J. Clin. Invest. Brian T. Fife, et al. 116:2252 doi:10.1172/JCI27856 [Go to this article.]

Figure 1
Tg⁺ scαCTLA-4 expression. Flow cytometric analysis was performed on splenocytes from scαCTLA-4 Tg⁺ mice and littermate controls using soluble murine fusion protein mCTLA-4 Ig and anti-B220. (A) Upper panels demonstrate scαCTLA-4 on naive Tg⁺ B cells and activated Tg⁺ B cells following anti-IgM stimulation (48 hours, 1 μg/ml) compared with FVB littermate negative controls (lower panels). All plots were gated on B220⁺ B cells. (B) Flow cytometric analysis was performed on thymocytes from scαCTLA-4 Tg mice and littermate controls as described above. Flow plots illustrate scαCTLA-4 expression in DP CD4⁺CD8⁺ thymocytes from scαCTLA-4 Tg⁺ mice, but not DP CD4⁺CD8⁺ thymocytes from FVB or SP CD4⁺ and SP CD8⁺ from scαCTLA-4 Tg⁺ or FVB Tg^– controls. Results shown are representative of 3 independent experiments with ≥ 3 mice per group.